Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Defining new standards of care for men with prostate cancer

Improving the outcomes of medical or surgical castration for men with prostate cancer has been an elusive goal since the approach was first reported in the 1940s.1 However, this situation changed at the annual American Society of Clinical Oncology meeting in 2014, when results reported from the ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease (CHAARTED) showed that addition of six cycles of docetaxel to standard of care (testosterone lowering hormone therapy) prolonged the survival of men with metastatic disease at the time of diagnosis relative to treatment with hormones alone.

email